Intravenous device and method for removing of myoglobin from circulating blood

• US 7,645,257 B2
• Filed: 11/09/2004
• Issued: 01/12/2010
• Est. Priority Date: 11/11/2003
• Status: Expired due to Fees

• Current Assignee: Amr Ali Al-Hossary
• Original Assignee: Amr Ali Al-Hossary
• Inventors: Al-Hossary, Amr Ali
• Primary Examiner(s): Mondesi; Robert B
• Assistant Examiner(s): PORTNER, VIRGINIA ALLEN
• Application Number:
  US10/578,673
• Publication Number:
  US 20070082396A1
• Time in Patent Office: 1,890 Days
• Field of Search: None
• US Class Current: 604/35
• CPC Class Codes: A61F 2/0077 Special surfaces of prostheses, e.g. for improving ingrowth A61F2/30767 takes precedence
• CPC Class Codes: A61F 2/01 Filters implantable into blood vessels
• CPC Class Codes: A61F 2230/0006 circular
• CPC Class Codes: A61F 2230/006 Y-shaped
• CPC Class Codes: A61F 2250/0059 temporary

Abstract

Prevention of Acute Renal Failure following myoglobinemia in cases of rhabdomyolysis by means of trapping myoglobin released to circulation following striated muscles injury using a temporary intravenous filter, hence prophylaxis of Acute Renal Failure, which commonly follows this situation. It is directed to all cases of rhabdomyolysis especially for “In situ prevention” in cases of disasters, crush injuries, and reperfusion injury in a limb.

Claims

1. An intravenous device comprising of a rod of a shape and size for insertion into a vein, the red being coated with a sheath, and the sheath being coated with anti-myoglobin antibodies able to remove myoglobin from circulating blood.

2. The intravenous device of claim 1, wherein the rod is a wire.

3. The intravenous device of claim 1, wherein the sheath is latex.

4. The intravenous device of claim 1, wherein the anti-myoglobin antibodies are latex particle immobilized anti-myoglobin antibodies.

5. A cannula comprising the intravenous device of claim 4.

6. The cannula of claim 5, wherein the cannula comprises a tip.

7. The cannula of claim 6, wherein the cannula is a cylindrical shape with a central core into which the intravenous device is inserted, wherein the intravenous device can protrude from the tip end of the cannula.

8. The cannula of claim 7, wherein the antimyoglobin antibodies are coated over the whole surface area that protrudes from the tip end of the cannula.

9. A method comprising the steps of:

Percutaneously introducing the cannula of claim 5 into a vein of a patient,

Removing the intravenous device from the patient after a period of time during which myoglobin is trapped by the antimyoglobin antibodies,

Reintroducing another intravenous device through the central core of cannula into the patient'"'"'s vein to trap additional circulating myoglobin as needed, then removing the cannula and intravenous device from the patient.

10. The method of claim 9, wherein the patient is at risk of Acute Renal Failure, rhabdomyolysis, or myoglobinemia.

11. The method of claim 10, wherein the risk of Acute Renal Failure is associated with earthquakes, orthopedic problems, alcohol and heroin use, occlusion of muscular vessels, crush injuries, compartment syndrome, or reperfusion injury in a limb.

12. The method of claim 11, wherein the reperfusion injury in a limb is associated with operative reperfusion.

13. The method of claim 9, wherein the vein is the vina cava, internal jugular vein, femoral vein.